Enduro Genetics Lands €12M Investment to Expand Bioproduction Technology

• Enduro Genetics has raised €12 million in Series A funding from Supernova Invest, NOON Ventures, and Sandwater.

• The investment will support the expansion of Enduro’s technology platform and accelerate commercialization efforts.

Enduro Genetics, a biotech startup has secured €12 million in Series A funding to advance its synthetic biology platform and scale commercialization. The investment comes from Supernova Invest, NOON Ventures, and Sandwater, bringing the company’s total funding to €18 million, including grants from the BioInnovation Institute and the European Innovation Council accelerator grant.

The startup is tackling a long-standing challenge in biomanufacturing: the decline in production efficiency at an industrial scale. In processes that rely on genetically engineered microorganisms, cells tend to mutate over time, prioritizing survival over production. Enduro Genetics addresses this issue with its patented “synthetic addiction” technology, which ensures that only high-producing cells survive and thrive.

“This new fundraise is a key milestone for Enduro. It is a testament to the team, the impact potential of our technology, and the market validation we have achieved over the last two years,” said Christian Munch, CEO of Enduro Genetics. “The funding allows us to accelerate our commercialization efforts, strengthen our technology platform, and expand the technology for use in biopharmaceutical expression systems.”

Founded by CSO Peter Rugbjerg, Enduro Genetics already works with leading biopharma, food, agriculture, and industrial players. The company sees its technology as a key enabler for industries adopting biomanufacturing to create sustainable alternatives to fossil-based products, such as biofuels, bioplastics, and specialty chemicals.